FREE ELECTRONIC LIBRARY - Dissertations, online materials

Pages:     | 1 |   ...   | 5 | 6 || 8 | 9 |   ...   | 18 |

«14 CSR White Paper Economy ESG Investing as an e Unchanging Face of Japanese Antidote to Myopic Employment Management International A airs Japanese ...»

-- [ Page 7 ] --

Once these patents expired, cheaper generic drugs would enter the market. This may be a welcome development from the patients’ perspective, since they would be able to purchase drugs with proven effectiveness and well-known side effects at lower prices. It would also be a boon for public health insurance schemes facing severe fiscal constraints and expanding demand for medical services. But for the pharmaceutical sector, a market dominated by generic drugs would make it difficult to secure the funds for the development of new drugs, hindering research and slowing advances in medicinal technology.

This was the impetus for the flurry of corporate acquisitions focusing on specialized, research-orientated companies, as the giant pharmaceuticals sought new platforms for the development of new drugs.

Takeda was no exception. Its patents on drugs that accounted for ¥100 billion in annual sales, including proton-pump inhibitor Takepron, were due to expire around 2010. To minimize this impact, the company needed to quickly bring new products to market. In 2008 Takeda purchased Millennium Pharmaceuticals for approximately ¥900 billion, and in 2011 it acquired Nycomed International Management for ¥11 trillion (prices and exchange rates at the time of merger).

Avoiding Pitfalls

The effort to globalize its operations and emerge as a leading player had the unanticipated consequence of bringing Takeda face to face with a new challenge: one that was closely linked to the industry’s relationship with society.

In March 2001, a group of 39 European and North American pharmaceutical companies took the South African government to court to protest a new law allowing the import and manufacture of generic copies of patented HIV/AIDS drugs. The companies argued that if the South African legislation went unchallenged, the international patent and intellectual property system would be undermined.

The government, along with international NGOs, countered that there were large numbers of people with HIV/AIDS in Africa and that neither individuals nor governments had the financial resources to cover the cost of treatment. They

44 CSR White PaPeR

stressed that the drugs were expensive because of the patent licenses and that without them it would be possible to save many lives.

In April 2011 the 39 companies dropped their suit, partly to prevent a deterioration in their image. By then, though, the damage had been done; public opinion not just in South Africa but all over the world turned against Big Pharma, which was seen as putting business and profits ahead of human lives.

As noted above, the development of new drugs requires a huge investment, and very few new drugs actually make it to market. If a company is unable to sell their products at appropriate prices, the business will become unsustainable, and the development of the next generation of drugs will come to a halt. To that extent, the pharmaceutical companies had a right to protest.

But the legal action taken by the European and American firms sparked an outrage. The number of people with HIV is still rising, although the pace has moderated somewhat, and the disease has yet to be brought under control. The share of HIV patients is particularly high in sub-Saharan Africa, with infection rates increasing in extremely poor areas—where 7 in 10 people live on less than $2 a day.

If we consider that the mission of pharmaceutical companies is to contribute to the health of people around the world through the provision of medical drugs, can we still say that they were justified in launching their lawsuit?

This experience prompted many pharmaceutical companies to rethink their ties with and their mission in society as they realized that a weak relationship could become a risk affecting the company’s entire operations.

Having joined the ranks of the industry’s top global companies, Takeda, too, took this lesson to heart. Both management and labor came to the understanding that CSR activities to “sustain” corporate value meant maintaining a vigilant, risk-management watch over social issues.

Identifying Common Social Concerns

Takeda’s corporate mission is to “strive towards better health for people worldwide through leading innovation in medicine”—a goal that in itself lies at the heart of corporate social responsibility. The company seeks to improve business operations with a full awareness of how its entire value chain affects its various stakeholders and works to create a sustainable society as a good corporate citizen.

How, then, is it going about integrating its business pursuits with efforts to resolve social issues? Takeda’s approach is quite unique.

It identifies material issues common to global companies through participation in UN Global Compact LEAD conferences and annual Business for Social Respon

–  –  –

Figure 1. Three-Step Process for Identifying Material Issues * IFPMA = International Federation of Pharmaceutical Manufacturers and Associations sibility (BSR) conferences, as well as by actively engaging in discussions with international organizations and NGOs (Section 1, Figure 1).

It also identifies material issues specific to the global pharmaceutical industry by participating in conferences of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the BSR Healthcare Working Group and conducting discussions with the Global Fund to Fight AIDS, Tuberculosis, and Malaria and other healthcare NGOs (Section 2, Figure 1). This gives the company a fuller understanding of global trends by learning about the issues other companies are facing and—through participation in such trendsetting projects as those of the International Integrated Reporting Council (IIRC)—allows it to lead the discussion between pharmaceutical companies and other industries.

These two initiatives help Takeda to identify those social issues that it is in the best position to address in the light of its management strategies and within the confines of its management resources.

The conclusions Takeda reached through this process were that it can best address two material issues. The first is comprehensive “access to healthcare” for people around the world through both its business operations and corporate citizenship activities. The second is “value chain management,” under which it advances CSR initiatives at each stage of the value chain within the core ISO 26000 framework.

–  –  –

Figure 2. International Conferences Attended by Takeda (June 2012 to June 2013) Source: Takeda Pharmaceutical 2013 annual report.

The former covers corporate citizenship activities aimed at “creating” corporate value, while the latter seeks to fully integrate CSR into business operations with a view to “sustaining” corporate value.

Sompo Japan’s CSR focuses on dialogue with stakeholders and Itochu’s on an employee-based bottom-up approach. Takeda’s CSR, meanwhile, involves ongoing discussions with other global companies, including pharmaceutical firms, and their civil-sector partners to examine the role the company should play in society, the relationship it should seek to build with society, and ways to more fully integrate its business operations with initiatives that help meet society’s needs. This is the path that is enabling Takeda to both bolster its corporate vision and strengthen risk management.

Traveling around the world to take part in various international forums may seem like a luxury (Figure 2). But this is probably the most efficient and effective way for Takeda to create and sustain its corporate value. As the fallout from the lawsuit in South Africa shows, a company risks severe damage to its business if it fails to build a strong relationship with society. Given the broad array of issues to

47 CSR White PaPeR

address, there is no telling what, when, and where problems may arise. Since there is a limit to what one company can do to keep abreast of various social developments, the most rational course of action is to maintain dialogue with other pharmaceutical companies and international NGO that are keeping an eye on such changes.

Sharing Case Studies

In identifying material issues, Takeda pays particularly close attention to risks and crises that other companies have faced in dealing with society. The South Africa court case is just one example of the risks that pharmaceutical companies constantly face. Because they are engaged at the leading edge of bioethics, companies may even become the source of new social controversies.

With environmental protection rules growing tougher, moreover, new issues may come to the fore. Drugs taken by patients may find their way into rivers and seas, disrupting the food chain and posing a danger to people and other living organisms. No longer is it enough for a company to focus its attention on simply providing effective drugs to help patients recover from illness and improve their health.

There are many pitfalls for globally active companies. Those that have operated only in Japan may not fully appreciate the different values peoples in other countries have. “Sustaining” corporate value is a task requiring both managers and staff to look at issues from the viewpoint of people on the ground.

The CSR department at Takeda thus actively collects and internally shares case

studies of risks and crises faced by other relevant companies around the world:

those affecting global companies in general, those impacting the chemical and food industries, and those pertaining particularly to global pharmaceutical companies (Figure 3).

This information enables management and individual departments to assess risks more accurately. The steady sharing of information has led Takeda employees Figure 3. Case Studies Shared by Takeda’s CSR Department

–  –  –

Figure 4. CSR Guidelines for Reference Source: Takeda Pharmaceutical 2013 annual report.

at all levels to give greater thought to the company’s relationship with society in their daily activities.

Embracing International CSR Guidelines Takeda has thus been quite successful in integrating its business operations with efforts to address social issues. It has also made effective use of international CSR guidelines.

Its initiatives are quite transparent to the public (Figure 4): Its basic principles are informed by the Global Compact; analysis and implementation are guided by ISO 26000; disclosures are made in accordance with the Global Reporting Initiative; and accountable dialogue is advanced based on the AA1000 guidelines of Britain’s AccountAbility.

Some companies may prefer to use their own standards. But international guidelines like the Global Compact and ISO 26000 offer the benefit of expertise

–  –  –

accumulated through dialogue with stakeholders around the world. Takeda makes active use of these public resources—something made possible by the thorough understanding of these guidelines by its CSR officers.

Addressing Social Issues through the Value Chain Takeda skillfully utilizes the guidelines to identify and address various social issues through the value chain. Gaining a grasp of a full range of social issues on one’s own can be a daunting task, so the company refers to the seven “core subjects” of ISO 26000 in analyzing its social responsibilities to both help create and sustain corporate value (Figure 5).

One core subject is human rights. Takeda highlights possible issues along the value chain, from research and development (including clinical trials) to procurement, production, distribution, and sales and marketing, so that each department has a full awareness of what to keep in mind.

For example, the research department conducts its activities in line with a set of policies and rules aimed at respecting dignity and human rights. Specifically, a Research Ethics Investigation Committee has been set up to deliberate on issues like the use of such human-derived specimens as blood, tissue, and cells.

Figure 5: Addressing Core Subjects in the Value Chain Source: Takeda Pharmaceutical 2013 annual report.

–  –  –

To address issues in procurement, production, and distribution, meanwhile, the company established a Global Purchasing Policy and Guidelines for Socially Responsible Purchasing calling for the rights of all people to be respected and the elimination of discriminatory or unfair practices based on nationality, race, ethnicity, creed, religion, gender, age, disability, disease, or social status. In addition to rooting out discrimination in its own operations, Takeda shares these principles with its suppliers and encourages their implementation.

The important thing is to think ahead in identifying relevant issues and considering what action to take. Most companies surveyed or interviewed by the Tokyo Foundation for the white paper had few initiatives regarding human rights other than organizing conventional workshops for employees.

Only when these issues are fully incorporated into the value chain, as Takeda has done, though, will they be perceived as being part of a company’s routine business operations.

Vaccines to Fight Communicable Diseases

In its efforts to create corporate value, Takeda prioritizes two CSR material issues:

“access to healthcare” and “value chain management.” The latter has been described above, so the former will be discussed here.

Access to healthcare refers to the broad range of initiatives aimed at enhancing the availability of healthcare services for people around the world. Part of this effort involves addressing unmet medical needs—situations where medical services are locally unavailable or where effective treatment does not yet exist. This can mean dealing with situations in developing countries where economic conditions prevent people from receiving existing vaccines or treatment and also cases in richer countries where preventative medicine or treatment has not yet been developed.

Pages:     | 1 |   ...   | 5 | 6 || 8 | 9 |   ...   | 18 |

Similar works:

«NBER WORKING PAPER SERIES CREDIT SUPPLY AND HOUSE PRICES: EVIDENCE FROM MORTGAGE MARKET SEGMENTATION Manuel Adelino Antoinette Schoar Felipe Severino Working Paper 17832 http://www.nber.org/papers/w17832 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 February 2012 We thank Viral Acharya, Chris Foote, Gustavo Manso, Atif Mian, Sendhil Mullainathan, Chris Mayer, David Scharfstein, Todd Sinai, Mathew Slaughter, Jeremy Stein, Bill Wheaton and seminar participants...»

«Pacific Rim Real Estate Society (PRRES) Conference 2006 Auckland January 22-25, 2006 Valuation variation – Result from a repeated experiment 1 Stellan Lundström2 and Christina Gustafsson3 Keywords: Uncertainty, valuation experiment, accounting, financial reporting 1 An earlier version of this paper was presented at the ERES Conference in Helsinki 2003. 2 Contact author: Professor in Real Estate Economics, Head of department, Director of the KTH Centre for Banking & finance. Address: Division...»

«Repo Haircuts and Economic Capital Wujiang Lou1 st 1 Draft CNY, February 8, 2016; Revision 3/21/2016 Abstract This article presents a model of haircuts and economic capital for repos. We propose a credit approach to solve haircuts such that the exposure to market risk meets a prescribed credit rating scale measured by expected loss. Specifically for securities financing business, a credit risk capital approach is also adopted where the borrower dependent haircut is set to a level such that the...»

«Ogaga Okuyade College of Education, Warri, Nigeria Recent Nigerian bards and minstrels: Forms of counter narratives Abstract: Most African cultural productions, especially literature and music, have remained political even in the post-Colonial era because of the dismal socio-political and economic conditions of the African people. Thus, African literature and music are not only very indicting, they have become media for artists to express their discontent over the failure of independence and...»

«IMPLEMENTING INFORMATION SYSTEMS TO SUPPORT KNOWLEDGE WORK: AN EXPLORATION OF WORK MOTIFS Davis, Christopher J., College of Business, University of South Florida St Petersburg. davisc@stpt.usf.edu Hunagel, Ellen M., College of Business, University of South Florida St Petersburg. hufnagel@stpt.usf.edu Abstract The research presented in this paper is part of a larger study of the organizational impacts of information systems on knowledge work. The phase of the research reported in the paper...»

«Symmetry: Art and Science Tihany Congress, 2004 Folk Architecture – Vernacular Architecture An International Conference, Hungary, 2012 Appendix PROPORTION ANALYSES OF TRADITIONAL VERNACULAR ARCHITECTURE (TVA) Joachim Langhein Name: Dr. Joachim Langhein, Economist, Ecologist, Geographer, Japanologist, private Researcher on Proportion in Architecture since 1978, global human ecology (since 1969) Born in Potsdam, Germany, 1942), grown up in Hamburg-Volksdorf, 2 years Berlin, since 1958...»

«Adam Glass structured finance and derivatives articles. September 2000 October 2004 Contents Margin rules create trap for unwary purchasers of CBO debt (part one) Margin rules create trap for unwary purchasers of CBO debt (part two) Margin rules create trap for unwary purchasers of CBO debt (part three) No geniuses need apply (part one) No geniuses need apply (part two) One duck falls: the saga of a 'compelling trade' Part I: The 'Quiet Period' Hits the Headlines One duck falls: the saga of a...»

«WP/12/251 Workers’ Remittances: An Overlooked Channel of International Business Cycle Transmission? Adolfo Barajas, Ralph Chami, Christian Ebeke, and Sampawende J. A. Tapsoba © 2012 International Monetary Fund WP/12/251 IMF Working Paper Middle East and Central Asia Department Workers’ Remittances: An Overlooked Channel of International Business Cycle Transmission? Prepared by Adolfo Barajas, Ralph Chami, Christian Ebeke, and Sampawende J.A. Tapsoba1 Authorized for distribution by Ralph...»

«Of Messiness, Systems and Sustainability: Towards a more social and environmental finance and accounting[1] Rob Gray The Centre for Social and Environmental Accounting Research Department of Accounting and Finance University of Glasgow Glasgow, G12 8LE r.h.gray@accfin.gla.ac.uk A paper prepared for plenary presentation at the British Accounting Association Annual Conference, Jersey, April 2002 DRAFT 5A: September 2002 Abstract This essay is a personal attempt at a re-visitation and...»

«Università degli Studi di Salerno CENTRO DI ECONOMIA DEL LAVORO E DI POLITICA ECONOMICA Sergio Destefanis* Vania Sena** PUBLIC CAPITAL AND TOTAL FACTOR PRODUCTIVITY. NEW EVIDENCE FROM THE ITALIAN REGIONS *CELPE _ Università degli Studi di Salerno – destefanis@unisa.it **LUBS – University of Leeds UK DISCUSSION PAPER N. 73 Febbraio 2003 1 CENTRO DI ECONOMIA DEL LAVORO E DI POLITICA ECONOMICA Comitato Scientifico: Adalgiso Amendola, Floro Ernesto Caroleo, Ugo Colombino, Cesare Imbriani,...»

«Financial Innovation and Money Demand: Evidence from Sub-Saharan Africa J Paul Dunne and Elizabeth Kasekende ERSA working paper 583 February 2016 Economic Research Southern Africa (ERSA) is a research programme funded by the National Treasury of South Africa. The views expressed are those of the author(s) and do not necessarily represent those of the funder, ERSA or the author’s affiliated institution(s). ERSA shall not be liable to any person for inaccurate information or opinions contained...»

«Free Stuff for Kids: Hundreds of Free and Up-To-A-Dollar Things Kids Can Send for by Mail Free Stuff the publication due to the entire enjoyable deals plus the truth that they can get nice stuff throughout the Free Stuff for Kids: Hundreds of Free and Up-To-A-Dollar Things Kids Can Send for by Mail mail. This most recent version encompasses a large machine part with deals for plenty of net freebies, in addition to it ordinary offers. Free Stuff For Kids Hundreds Of Free And Up To A Dollar...»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.